YTHDF2 and intrahepatic cholangiocarcinoma: Furthermore, YTHDF2 increased CDKN1B mRNA degradation in an m6A-dependent manner, which promoted intrahepatic cholangiocarcinoma (ICC) progression and reduced sensitivity to cisplatin treatment [121].